Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Drotrecogin alfa (activated): real-life use and outcomes for the UK. | Available online http content 1 2 2 R58 Open Access Research Drotrecogin alfa activated real-life use and outcomes for the UK Kathryn M Rowan Catherine A Welch Emma North and David A Harrison Intensive Care National Audit Research Centre Tavistock House Tavistock Square London WC1H 9HR UK Corresponding author Kathryn M Rowan Received 13 Aug 2007 Revisions requested 28 Sep 2007 Revisions received 18 Jan 2008 Accepted 22 Apr 2008 Published 22 Apr 2008 Critical Care 2008 12 R58 doi cc6879 This article is online at http content 12 2 R58 2008 Rowan et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction In March 2001 the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis PROWESS study were published which indicated a absolute reduction in 28-day mortality. Drotrecogin alfa activated DrotAA was subsequently approved for use in patients with severe sepsis. Methods In December 2002 critical care units in England Wales and Northern Ireland were invited to participate in an audit of DrotAA. Data for each infusion of DrotAA were linked to case mix and outcome data from a national audit. Use of DrotAA was described and a nonrandomized comparison of effectiveness was conducted. Results 1 292 infusions of DrotAA were recorded in 112 units 61 commenced during the first 24 hours in the unit. The majority 77 of patients had three or more organs failing lung 42 and abdomen 40 were the most common primary sites of infection. Crude hospital mortality was high 45 at 28 days only 18 had left acute hospital and 19 were still in the unit. For 30 the full 96-hour infusion was not completed 24 of infusions were interrupted .
